Table 2 Participant characteristics of patients with pediatric uveitis and pediatric controls
From: Involvement of the systemic microcirculation in pediatric uveitis
Demographics | Uveitis | Pediatric controls | P-value |
|---|---|---|---|
Number of subjects | 119 | 25 | Â |
Male sex, n (%) | 52 (44) | 13 (52) | 0.54 |
Mean age in years (SD) | 13.7 (3) | 9.1 (4) | < 0.001 |
Type of uveitis, n (%) | Â | NA | Â |
 Anterior | 55 (46) | ||
 Intermediate | 21 (18) | ||
 Panuveitis | 43 (36) | ||
Associated systemic disease, n (%) | Â | NA | Â |
 None | 62 (52) | ||
 JIA | 38 (32) | ||
 Presumed TINU syndrome | 13 (11) | ||
 Othera | 6 (5) | ||
 Disease duration of uveitis in years | 4.7 (4) | NA |  |
Type of JIA, n (%) | |||
 Monoarthritis | 2 | NA |  |
 Oligoarthritis | 28 |  |  |
 Polyarthritis | 8 |  |  |
 ANA seropositive, n (%) | 60 (50) | NA |  |
Systemic treatment, n (%) | |||
 None | 25 (21) | 25 (100) |  |
Corticosteroids | 16 (13) | 0 | Â |
 Methotrexate | 45 (38) | 0 |  |
 Mycophenolate mofetil | 45 (38) | 0 |  |
 Adalimumab | 36 (30) | 0 |  |
 Infliximab | 3 (3) | 0 |  |
 Tocilizumab | 10 (8) | 0 |  |
 Otherb | 4 (3) | 0 |  |